Screener
Aurinia Pharmaceuticals AUPH Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValueOutstanding.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 177,398 | 170,256 |
| Commitments and contingencies (Note 5) | ||
| Shareholders' equity | ||
| Common shares — no par value, Unlimited shares authorized, 132,907 and 132,323 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,117,248 | 1,120,035 |
| Additional paid-in capital | 76,192 | 111,263 |
| Accumulated other comprehensive loss | (977) | (599) |
| Accumulated deficit | (577,599) | (649,368) |
| Total shareholders' equity | 614,864 | 581,331 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's common stock?
- Aurinia Pharmaceuticals (AUPH) reported common stock of $1.12B in Q2 2026.
- How has Aurinia Pharmaceuticals's common stock changed year-over-year?
- Aurinia Pharmaceuticals's common stock decreased by 0.5% year-over-year, from $1.12B to $1.12B.
- What is the long-term trend for Aurinia Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's common stock has grown at a 3.5% compound annual growth rate (CAGR), from $944.33M to $1.12B.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Aurinia Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude